comparemela.com

Latest Breaking News On - Institutional trading of rocket pharmaceuticals - Page 2 : comparemela.com

Cantor Fitzgerald Reiterates Overweight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $65.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 123.91% from the stock’s previous close. […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Reiterated by Cantor Fitzgerald

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They presently have a $65.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 122.76% from the stock’s current price. Several […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.